1 263 63 ADVANCES WITH LONG NON-CODING RNAS IN DIABETIC PERIPHERAL NEUROPATHY. LONG NON-CODING RNAS (?LNCRNAS) ?ARE A GROUP OF NON-CODING RNAS LONGER THAN 200 NUCLEOTIDES, WHICH ARE DEFINED AS TRANSCRIPTS. THE LNCRNAS ARE INVOLVED IN REGULATING GENE EXPRESSION AT EPIGENETIC, TRANSCRIPTIONAL, AND POST-TRANSCRIPTIONAL LEVELS. RECENT STUDIES HAVE FOUND THAT LNCRNA IS CLOSELY RELATED TO MANY DISEASES LIKE NEUROLOGICAL DISEASES, ENDOCRINE AND METABOLIC DISORDERS. DIABETIC PERIPHERAL NEUROPATHY (DPN) IS ONE OF THE MOST COMMON CHRONIC COMPLICATIONS OF DIABETES MELLITUS. IN THIS REVIEW, WE HIGHLIGHT THE LATEST RESEARCH RELATED TO LNCRNAS IN DPN. 2020 2 3374 16 HISTONE POST-TRANSLATIONAL MODIFICATIONS AS POTENTIAL THERAPEUTIC TARGETS FOR PAIN MANAGEMENT. EFFECTIVE PHARMACOLOGICAL MANAGEMENT OF PAIN ASSOCIATED WITH TISSUE PATHOLOGY IS AN UNMET MEDICAL NEED. TRANSCRIPTIONAL MODIFICATIONS IN NOCICEPTIVE PATHWAYS ARE PIVOTAL FOR THE DEVELOPMENT AND THE MAINTENANCE OF PAIN ASSOCIATED WITH TISSUE DAMAGE. ACCUMULATING EVIDENCE HAS SHOWN THE IMPORTANCE OF THE EPIGENETIC CONTROL OF TRANSCRIPTION IN NOCICEPTIVE PATHWAYS VIA HISTONE POST-TRANSLATIONAL MODIFICATIONS (PTMS). HENCE, HISTONE PTMS COULD BE TARGETS FOR NOVEL EFFECTIVE ANALGESICS. HERE, WE DISCUSS THE CURRENT UNDERSTANDING OF HISTONE PTMS IN THE MODULATION OF GENE EXPRESSION AFFECTING NOCICEPTION AND PAIN PHENOTYPES FOLLOWING TISSUE INJURY. WE ALSO PROVIDE A CRITICAL VIEW OF THE TRANSLATIONAL IMPLICATIONS OF PRECLINICAL MODELS AND DISCUSS OPPORTUNITIES AND CHALLENGES OF TARGETING HISTONE PTMS TO RELIEVE PAIN IN CLINICALLY RELEVANT TISSUE INJURIES. 2021 3 2218 21 EPIGENETIC MODIFICATIONS IN FIBROTIC DISEASES: IMPLICATIONS FOR PATHOGENESIS AND PHARMACOLOGICAL TARGETS. ORGAN FIBROSIS IS A COMPLEX AND CHRONIC DISORDER THAT RESULTS FROM A VARIETY OF ACUTE INJURIES AND CONTRIBUTES TO THIRTY PERCENT OF NATURALLY OCCURRING DEATHS WORLDWIDE. THE MAIN FEATURE OF ORGAN FIBROSIS IS THE EXCESSIVE ACCUMULATION AND DEPOSIT OF EXTRACELLULAR MATRIX, THEREBY LEADING TO ORGAN DYSFUNCTION, LOSS OF ELASTICITY, AND DEVELOPMENT OF A RIGID ORGAN. ACCUMULATING EVIDENCE SHOWS THAT EPIGENETIC REMODELING, INCLUDING ABERRANT DNA METHYLATION AND NONCODING RNA EXPRESSION AS WELL AS HISTONE POST-TRANSLATIONAL MODIFICATIONS, PLAY IMPORTANT ROLES IN THE PATHOGENESIS OF FIBROSIS THROUGH THE REGULATION OF FIBROBLAST ACTIVATION, DIFFERENTIATION, AND APOPTOSIS, AS WELL AS COLLAGEN SYNTHESIS AND PROFIBROTIC GENE TRANSCRIPTION. IN THIS REVIEW, WE DISCUSS THE BASIC REGULATION OF DNA METHYLATION, NONCODING RNA EXPRESSION, AND HISTONE POST-TRANSLATIONAL MODIFICATION, AND THEIR PARTICIPATION IN THE PATHOGENESIS AND DEVELOPMENT OF ORGAN FIBROSIS. THIS REVIEW ALSO PROVIDES THE LATEST INSIGHTS INTO THE NOVEL BIOMARKERS AND THERAPEUTIC TARGETS FOR FIBROSIS THROUGH MODULATION OF EPIGENETIC REMODELING. 2015 4 5563 23 ROLE OF HISTONE POST-TRANSLATIONAL MODIFICATIONS IN INFLAMMATORY DISEASES. INFLAMMATION IS A DEFENSIVE REACTION FOR EXTERNAL STIMULI TO THE HUMAN BODY AND GENERALLY ACCOMPANIED BY IMMUNE RESPONSES, WHICH IS ASSOCIATED WITH MULTIPLE DISEASES SUCH AS ATHEROSCLEROSIS, TYPE 2 DIABETES, ALZHEIMER'S DISEASE, PSORIASIS, ASTHMA, CHRONIC LUNG DISEASES, INFLAMMATORY BOWEL DISEASE, AND MULTIPLE VIRUS-ASSOCIATED DISEASES. EPIGENETIC MECHANISMS HAVE BEEN DEMONSTRATED TO PLAY A KEY ROLE IN THE REGULATION OF INFLAMMATION. COMMON EPIGENETIC REGULATIONS ARE DNA METHYLATION, HISTONE MODIFICATIONS, AND NON-CODING RNA EXPRESSION; AMONG THESE, HISTONE MODIFICATIONS EMBRACE VARIOUS POST-MODIFICATIONS INCLUDING ACETYLATION, METHYLATION, PHOSPHORYLATION, UBIQUITINATION, AND ADP RIBOSYLATION. THIS REVIEW FOCUSES ON THE SIGNIFICANT ROLE OF HISTONE MODIFICATIONS IN THE PROGRESSION OF INFLAMMATORY DISEASES, PROVIDING THE POTENTIAL TARGET FOR CLINICAL THERAPY OF INFLAMMATION-ASSOCIATED DISEASES. 2022 5 5577 25 ROLE OF MICRORNAS IN THE PATHOPHYSIOLOGY OF ADDICTION. ADDICTION IS A CHRONIC AND RELAPSING BRAIN DISORDER CHARACTERIZED BY COMPULSIVE SEEKING DESPITE ADVERSE CONSEQUENCES. THERE ARE BOTH HERITABLE AND EPIGENETIC MECHANISMS UNDERLYING DRUG ADDICTION. EMERGING EVIDENCE SUGGESTS THAT NON-CODING RNAS (NCRNAS) SUCH AS MICRORNAS (MIRNAS), LONG NON-CODING RNAS, AND CIRCULAR RNAS REGULATE SYNAPTIC PLASTICITY AND RELATED BEHAVIORS CAUSED BY SUBSTANCES OF ABUSE. THESE NCRNAS MODIFY GENE EXPRESSION AND MAY CONTRIBUTE TO THE BEHAVIORAL PHENOTYPES OF ADDICTION. AMONG THE NCRNAS, THE MOST WIDELY RESEARCHED AND IMPACTFUL ARE MIRNAS. THE GOAL IN THIS SYSTEMATIC REVIEW IS TO PROVIDE A DETAILED ACCOUNT OF RECENT RESEARCH INVOLVING THE ROLE OF MIRNAS IN ADDICTION. THIS ARTICLE IS CATEGORIZED UNDER: RNA INTERACTIONS WITH PROTEINS AND OTHER MOLECULES > SMALL MOLECULE-RNA INTERACTIONS RNA IN DISEASE AND DEVELOPMENT > RNA IN DISEASE. 2021 6 4315 27 MICRORNAS AS NEW TARGETS OF DIETARY POLYPHENOLS. IN THE LASTS YEARS IT HAS BECOME EVIDENT THAT POLYPHENOLS MODIFY CELL FUNCTIONALITY THROUGH EPIGENETIC MECHANISMS, SUCH AS MODULATING MICRORNA (MIRNA) LEVELS. MIRNAS ARE SMALL NON-CODING RNAS OF ABOUT 22 NUCLEOTIDES IN LENGTH, THAT MODULATE GENE EXPRESSION AT THE POST-TRANSCRIPTIONAL LEVEL. MIRNAS ARE INVOLVED IN ALMOST ALL BIOLOGICAL PROCESSES, AFFECT MOST METABOLIC PATHWAYS AND RECENT EVIDENCE SUGGESTS THEIR DYSREGULATION IN A NUMBER OF METABOLIC DISORDERS AND DISEASES. IN THIS SENSE, MIRNAS ARE EMERGING AS POTENTIAL BIOMARKERS OF NUMEROUS PATHOLOGIES AND THEREFORE AS NEW THERAPEUTIC TARGETS. POLYPHENOLIC MODULATION OF MIRNAS IS VERY ATTRACTIVE AS A STRATEGY TO TARGET NUMEROUS CELL PROCESSES AND POTENTIALLY REDUCE THE RISK OF CHRONIC DISEASES. 2014 7 4336 26 MICRORNAS: THE UNDERLYING MEDIATORS OF PATHOGENETIC PROCESSES IN VASCULAR COMPLICATIONS OF DIABETES. DIABETES MELLITUS CAUSES CHRONIC COMPLICATIONS PRIMARILY AFFECTING THE VASCULATURE OF VARIOUS ORGANS, RISKING PATIENTS FOR RENAL FAILURE, VISION LOSS AND HEART FAILURE. A NEWLY DISCOVERED CLASS OF MOLECULES, MICRORNAS, MAY BE IMPORTANT IN THE GENESIS OF THESE PATHOLOGIC PROCESSES. MICRORNAS REGULATE GENE EXPRESSION AT THE POST-TRANSCRIPTIONAL LEVEL BY INHIBITING TARGET MESSENGER RNA TRANSLATION. IN DISEASE STATES, HOWEVER, THE EXPRESSION OF MICRORNAS OFTEN IS ALTERED, RESULTING IN FURTHER ALTERED EXPRESSION (MOSTLY OVEREXPRESSION) OF DOWNSTREAM TARGET GENES. INTERESTINGLY, RESTORING MICRORNA EXPRESSION TO NORMAL LEVELS CAN CORRECT DOWNSTREAM EFFECTS AND PREVENT DIABETES-ASSOCIATED CHANGES. INVESTIGATIONS INTO MICRORNA INVOLVED IN VARIOUS PATHOGENETIC PROCESSES MEDIATING DIABETIC NEPHROPATHY, RETINOPATHY AND CARDIOMYOPATHY ARE HIGHLIGHTED IN THIS REVIEW. FUTURE DIRECTIONS OF MICRORNA IN THERAPEUTICS AND DIAGNOSTICS ARE ALSO DISCUSSED. IT IS OUR INTENT TO HELP THE READER APPRECIATE THE DIVERSE INTERACTIONS MICRORNAS HAVE IN CELLULAR SIGNALLING AND HOW UNDERSTANDING EPIGENETIC ELEMENTS, SUCH AS MICRORNAS, POTENTIALLY CAN YIELD NEW THERAPEUTIC STRATEGIES. 2013 8 4451 32 MOLECULAR MECHANISMS AND FUNCTIONS OF LNCRNAS IN THE INFLAMMATORY REACTION OF DIABETES MELLITUS. DIABETES IS A CHRONIC INFLAMMATORY STATE, AND SEVERAL STUDIES HAVE SHOWN THAT THE MECHANISMS OF INSULIN RESISTANCE AND ABNORMAL ISLET BETA-CELL FUNCTION IN DIABETES ARE CLOSELY RELATED TO INFLAMMATORY REACTIONS. INFLAMMATION PLAYS A CRITICAL ROLE IN DIABETIC COMPLICATIONS. LONG NONCODING RNAS (LNCRNAS), A NEW AREA OF GENOMIC RESEARCH FOR GENE REGULATION, HAVE COMPLEX BIOLOGICAL FUNCTIONS IN VARIOUS ASPECTS OF CELLULAR BIOLOGICAL ACTIVITY. RECENT STUDIES HAVE SHOWN THAT LNCRNAS ARE ASSOCIATED WITH THE REGULATION OF INFLAMMATORY RESPONSES IN VARIOUS WAYS, INCLUDING AT THE EPIGENETIC, TRANSCRIPTIONAL, AND POSTTRANSCRIPTIONAL LEVELS. THIS PAPER PRESENTS A BRIEF REVIEW OF STUDIES ON THE MECHANISMS OF LNCRNAS IN DIABETIC INFLAMMATION. THE PURPOSE OF THIS ARTICLE IS TO DETERMINE THE ROLE OF LNCRNAS IN THE PROCESS OF DIABETIC INFLAMMATION AND TO PROVIDE NEW STRATEGIES FOR THE USE OF LNCRNAS IN THE TREATMENTS FOR DIABETIC INFLAMMATION. 2021 9 1872 26 EMERGING ROLE OF LONG NON-CODING RNAS IN ENDOTHELIAL DYSFUNCTION AND THEIR MOLECULAR MECHANISMS. LONG NON-CODING RNAS (LNCRNAS) ARE THE NOVEL CLASS OF TRANSCRIPTS INVOLVED IN TRANSCRIPTIONAL, POST-TRANSCRIPTIONAL, TRANSLATIONAL, AND POST-TRANSLATIONAL REGULATION OF PHYSIOLOGY AND THE PATHOLOGY OF DISEASES. STUDIES HAVE EVIDENCED THAT THE IMPAIRMENT OF ENDOTHELIUM IS A CRITICAL EVENT IN THE PATHOGENESIS OF ATHEROSCLEROSIS AND ITS COMPLICATIONS. ENDOTHELIAL DYSFUNCTION IS CHARACTERIZED BY AN IMBALANCE IN VASODILATION AND VASOCONSTRICTION, OXIDATIVE STRESS, PROINFLAMMATORY FACTORS, AND NITRIC OXIDE BIOAVAILABILITY. DISRUPTION OF THE ENDOTHELIAL BARRIER PERMEABILITY, THE FIRST STEP IN DEVELOPING ATHEROSCLEROTIC LESIONS IS A CONSEQUENCE OF ENDOTHELIAL DYSFUNCTION. THOUGH SEVERAL FACTORS INTERFERE WITH THE NORMAL FUNCTIONING OF THE ENDOTHELIUM, INTRINSIC EPIGENETIC MECHANISMS GOVERNING ENDOTHELIAL FUNCTION ARE REGULATED BY LNCRNAS AND PERTURBATIONS CONTRIBUTE TO THE PATHOGENESIS OF THE DISEASE. THIS REVIEW COMPREHENSIVELY ADDRESSES THE BIOGENESIS OF LNCRNA AND MOLECULAR MECHANISMS UNDERLYING AND REGULATION IN ENDOTHELIAL FUNCTION. AN INSIGHT CORRELATING LNCRNAS AND ENDOTHELIAL DYSFUNCTION-ASSOCIATED DISEASES CAN POSITIVELY IMPACT THE DEVELOPMENT OF NOVEL BIOMARKERS AND THERAPEUTIC TARGETS IN ENDOTHELIAL DYSFUNCTION-ASSOCIATED DISEASES AND TREATMENT STRATEGIES. 2022 10 3957 24 LONG NON-CODING RNAS AS EMERGING REGULATORS OF MIRNAS AND EPIGENETICS IN DIABETES-RELATED CHRONIC KIDNEY DISEASE. DIABETES IS ONE OF THE MAJOR CAUSE OF CHRONIC KIDNEY DISEASE (CKD), INCLUDING "DIABETIC NEPHROPATHY," AND IS AN INCREASINGLY PREVALENT ACCELERATOR OF THE PROGRESSION OF NON-DIABETIC FORMS OF CKD. THE LONG NON-CODING RNAS (LNCRNAS) HAVE COME INTO THE LIMELIGHT IN THE PAST FEW YEARS AS ONE OF THE EMERGING WEAPONS AGAINST CKD IN DIABETES. AVAILABLE DATA OVER THE PAST FEW YEARS DEMONSTRATE THE INTERACTION OF LNCRNAS WITH MIRNAS AND EPIGENETIC MACHINERY. INTERESTINGLY, THE EVOLVING DATA SUGGEST THAT LNCRNAS PLAY A VITAL ROLE IN DIABETES-ASSOCIATED CKD BY REGULATION OF EPIGENETIC ENZYMES SUCH AS DNA METHYLTRANSFERASE, HISTONE DEACETYLASES, AND HISTONE METHYLTRANSFERASES. LNCRNAS ARE ALSO ENGAGED IN THE REGULATION OF SEVERAL MIRNAS IN DIABETIC NEPHROPATHY. HENCE THIS REVIEW WILL ELABORATE ON THE ASSOCIATION BETWEEN LNCRNAS AND THEIR INTERACTION WITH EPIGENETIC REGULATORS INVOLVED IN DIFFERENT ASPECTS AND THUS THE PROGRESSION OF CKD IN DIABETES. 2022 11 1021 27 CIRCULAR RNA AS AN EPIGENETIC REGULATOR IN CHRONIC LIVER DISEASES. CIRCULAR RNA (CIRCRNA) IS A TYPE OF NON-CODING RNA CHARACTERIZED BY A COVALENTLY CLOSED CONTINUOUS LOOP. CIRCRNA IS GENERATED BY PRE-MRNA THROUGH BACK-SPLICING AND IS PROBABLY CLEARED UP BY EXTRACELLULAR VESICLES. CIRCRNAS PLAY A PIVOTAL ROLE IN THE EPIGENETIC REGULATION OF GENE EXPRESSION AT TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL LEVELS. RECENTLY, CIRCRNAS HAVE BEEN DEMONSTRATED TO BE INVOLVED IN THE REGULATION OF LIVER HOMEOSTASIS AND DISEASES. HOWEVER, THE EPIGENETIC ROLE AND UNDERLYING MECHANISMS OF CIRCRNAS IN CHRONIC LIVER DISEASES REMAIN UNCLEAR. THIS REVIEW DISCUSSED THE ROLE OF CIRCRNAS IN NON-NEOPLASTIC CHRONIC LIVER DISEASES, INCLUDING ALCOHOLIC LIVER DISEASE (ALD), METABOLIC-ASSOCIATED FATTY LIVER DISEASE (MAFLD), VIRAL HEPATITIS, LIVER INJURY AND REGENERATION, LIVER CIRRHOSIS, AND AUTOIMMUNE LIVER DISEASE. THE REVIEW ALSO HIGHLIGHTED THAT FURTHER EFFORTS ARE URGENTLY NEEDED TO DEVELOP CIRCRNAS AS NOVEL DIAGNOSTICS AND THERAPEUTICS FOR CHRONIC LIVER DISEASES. 2021 12 5546 23 ROLE OF EPIGENETIC MECHANISMS IN THE DEVELOPMENT OF CHRONIC COMPLICATIONS OF DIABETES. THERE IS GROWING EVIDENCE THAT EPIGENETIC REGULATION OF GENE EXPRESSION INCLUDING POST-TRANSLATIONAL HISTONE MODIFICATIONS (PTHMS), DNA METHYLATION AND MICRORNA (MIRNA)-REGULATION OF MRNA TRANSLATION COULD PLAY A CRUCIAL ROLE IN THE DEVELOPMENT OF CHRONIC, DIABETIC COMPLICATIONS. HYPERGLYCEMIA CAN INDUCE AN ABNORMAL ACTION OF PTHMS AND DNA METHYLTRANSFERASES AS WELL AS ALTER THE LEVELS OF NUMEROUS MIRNAS IN ENDOTHELIAL CELLS, VASCULAR SMOOTH MUSCLE CELLS, CARDIOMYOCYTES, RETINA, AND RENAL CELLS. THESE EPIGENETIC ABNORMALITIES RESULT IN CHANGES IN THE EXPRESSION OF NUMEROUS GENES CONTRIBUTING TO EFFECTS SUCH AS DEVELOPMENT OF CHRONIC INFLAMMATION, IMPAIRED CLEARANCE OF REACTIVE OXYGEN SPECIES (ROS), ENDOTHELIAL CELL DYSFUNCTION AND/OR THE ACCUMULATION OF EXTRACELLULAR MATRIX IN THE KIDNEY, WHICH CAUSING THE DEVELOPMENT OF RETINOPATHY, NEPHROPATHY OR CARDIOMYOPATHY. SOME EPIGENETIC MODIFICATIONS, FOR EXAMPLE PTHMS AND DNA METHYLATION, BECOME IRREVERSIBLE OVER TIME. THEREFORE, THESE PROCESSES HAVE GAINED MUCH ATTENTION IN EXPLAINING THE LONG-LASTING DETRIMENTAL CONSEQUENCES OF HYPERGLYCAEMIA CAUSING THE DEVELOPMENT OF CHRONIC COMPLICATIONS EVEN AFTER IMPROVED GLYCAEMIC CONTROL IS ACHIEVED. OUR REVIEW SUGGESTS THAT THE TREATMENT OF CHRONIC COMPLICATIONS SHOULD FOCUS ON ERASING METABOLIC MEMORY BY TARGETING CHROMATIN MODIFICATION ENZYMES AND BY RESTORING MIRNA LEVELS. 2014 13 4784 22 NUTRIMIROMICS: ROLE OF MICRORNAS AND NUTRITION IN MODULATING INFLAMMATION AND CHRONIC DISEASES. NUTRIMIROMICS STUDIES THE INFLUENCE OF THE DIET ON THE MODIFICATION OF GENE EXPRESSION DUE TO EPIGENETIC PROCESSES RELATED TO MICRORNAS (MIRNAS), WHICH MAY AFFECT THE RISK FOR THE DEVELOPMENT OF CHRONIC DISEASES. MIRNAS ARE A CLASS OF NON-CODING ENDOGENOUS RNA MOLECULES THAT ARE USUALLY INVOLVED IN POST-TRANSCRIPTIONAL GENE SILENCING BY INDUCING MRNA DEGRADATION OR TRANSLATIONAL REPRESSION BY BINDING TO A TARGET MESSENGER RNA. THEY CAN BE CONTROLLED BY ENVIRONMENTAL AND DIETARY FACTORS, PARTICULARLY BY ISOLATED NUTRIENTS OR BIOACTIVE COMPOUNDS, INDICATING THAT DIET MANIPULATION MAY HOLD PROMISE AS A THERAPEUTIC APPROACH IN MODULATING THE RISK OF CHRONIC DISEASES. THIS REVIEW SUMMARIZES THE EVIDENCE REGARDING THE INFLUENCE OF NUTRIENTS AND BIOACTIVE COMPOUNDS ON THE EXPRESSION OF MIRNAS RELATED TO INFLAMMATION AND CHRONIC DISEASE IN SEVERAL MODELS (CELL CULTURE, ANIMAL MODELS, AND HUMAN TRIALS). 2017 14 5583 28 ROLE OF NON-CODING RNAS IN NON-AGING-RELATED NEUROLOGICAL DISORDERS. PROTEIN CODING SEQUENCES REPRESENT ONLY 2% OF THE HUMAN GENOME. RECENT ADVANCES HAVE DEMONSTRATED THAT A SIGNIFICANT PORTION OF THE GENOME IS ACTIVELY TRANSCRIBED AS NON-CODING RNA MOLECULES. THESE NON-CODING RNAS ARE EMERGING AS KEY PLAYERS IN THE REGULATION OF BIOLOGICAL PROCESSES, AND ACT AS "FINE-TUNERS" OF GENE EXPRESSION. NEUROLOGICAL DISORDERS ARE CAUSED BY A WIDE RANGE OF GENETIC MUTATIONS, EPIGENETIC AND ENVIRONMENTAL FACTORS, AND THE EXACT PATHOPHYSIOLOGY OF MANY OF THESE CONDITIONS IS STILL UNKNOWN. IT IS CURRENTLY RECOGNIZED THAT DYSREGULATIONS IN THE EXPRESSION OF NON-CODING RNAS ARE PRESENT IN MANY NEUROLOGICAL DISORDERS AND MAY BE RELEVANT IN THE MECHANISMS LEADING TO DISEASE. IN ADDITION, CIRCULATING NON-CODING RNAS ARE EMERGING AS POTENTIAL BIOMARKERS WITH GREAT POTENTIAL IMPACT IN CLINICAL PRACTICE. IN THIS REVIEW, WE DISCUSS MAINLY THE ROLE OF MICRORNAS AND LONG NON-CODING RNAS IN SEVERAL NEUROLOGICAL DISORDERS, SUCH AS EPILEPSY, HUNTINGTON DISEASE, FRAGILE X-ASSOCIATED ATAXIA, SPINOCEREBELLAR ATAXIAS, AMYOTROPHIC LATERAL SCLEROSIS (ALS), AND PAIN. IN ADDITION, WE GIVE INFORMATION ABOUT THE CONDITIONS WHERE MICRORNAS HAVE DEMONSTRATED TO BE POTENTIAL BIOMARKERS SUCH AS IN EPILEPSY, PAIN, AND ALS. 2018 15 1051 24 CLINICAL IMPLICATIONS OF EXOSOME-DERIVED NONCODING RNAS IN LIVER. EXOSOMES, ONE OF THREE MAIN TYPES OF EXTRACELLULAR VESICLES, ARE ~30-100 NM IN DIAMETER AND HAVE A LIPID BILAYER MEMBRANE. THEY ARE WIDELY DISTRIBUTED IN ALMOST ALL BODY FLUIDS. EXOSOMES HAVE THE POTENTIAL TO REGULATE UNKNOWN CELLULAR AND MOLECULAR MECHANISMS IN INTERCELLULAR COMMUNICATION, ORGAN HOMEOSTASIS, AND DISEASES. THEY ARE CRITICAL SIGNAL CARRIERS THAT TRANSFER NUCLEIC ACIDS, PROTEINS, LIPIDS, AND OTHER SUBSTANCES INTO RECIPIENT CELLS, PARTICIPATING IN CELLULAR SIGNAL TRANSDUCTION AND MATERIAL EXCHANGE. NCRNAS ARE NON-PROTEIN-CODING GENES THAT ACCOUNT FOR OVER 90% OF THE GENOME AND INCLUDE MICRORNAS (MIRNAS), LONG NCRNAS (LNCRNAS), AND CIRCULAR RNAS (CIRCRNAS). NCRNAS ARE CRUCIAL FOR PHYSIOLOGICAL AND PATHOLOGICAL ACTIVITIES IN THE LIVER BY PARTICIPATING IN GENE TRANSCRIPTION, POSTTRANSCRIPTIONAL EPIGENETIC REGULATION, AND CELLULAR PROCESSES THROUGH INTERACTING WITH DNA, RNA, OR PROTEINS. RECENT EVIDENCE FROM BOTH CLINICAL AND PRECLINICAL STUDIES INDICATES THAT EXOSOME-DERIVED NONCODING RNAS (NCRNAS) ARE HIGHLY INVOLVED IN THE PROGRESSION OF ACUTE AND CHRONIC LIVER DISEASES BY REGULATING HEPATIC LIPID METABOLISM, INNATE IMMUNITY, VIRAL INFECTION, FIBROSIS, AND CANCER. THEREFORE, EXOSOME-DERIVED NCRNAS HAVE PROMISING POTENTIAL AND CLINICAL IMPLICATIONS FOR THE EARLY DIAGNOSIS, TARGETED THERAPY, AND PROGNOSIS OF LIVER DISEASES. 2022 16 3772 23 INTERACTION BETWEEN MICRORNA AND DNA METHYLATION IN ATHEROSCLEROSIS. ATHEROSCLEROSIS (AS) IS A CHRONIC INFLAMMATORY DISEASE ACCOMPANIED BY COMPLEX PATHOLOGICAL CHANGES, SUCH AS ENDOTHELIAL DYSFUNCTION, FOAM CELL FORMATION, AND VASCULAR SMOOTH MUSCLE CELL PROLIFERATION. MANY APPROACHES, INCLUDING REGULATING AS-RELATED GENE EXPRESSION IN THE TRANSCRIPTIONAL OR POST-TRANSCRIPTIONAL LEVEL, CONTRIBUTE TO ALLEVIATING AS DEVELOPMENT. THE DNA METHYLATION IS A CRUCIAL EPIGENETIC MODIFICATION IN REGULATING CELL FUNCTION BY SILENCING THE RELATIVE GENE EXPRESSION. THE MICRORNA (MIRNA) IS A TYPE OF NONCODING RNA THAT PLAYS AN IMPORTANT ROLE IN GENE POST-TRANSCRIPTIONAL REGULATION AND DISEASE DEVELOPMENT. THE DNA METHYLATION AND THE MIRNA ARE IMPORTANT EPIGENETIC FACTORS IN AS. HOWEVER, RECENT STUDIES HAVE FOUND A MUTUAL REGULATION BETWEEN THESE TWO FACTORS IN AS DEVELOPMENT. IN THIS STUDY, RECENT INSIGHTS INTO THE ROLES OF MIRNA AND DNA METHYLATION AND THEIR INTERACTION IN THE AS PROGRESSION ARE REVIEWED. 2021 17 3640 24 INCREASED EXTRACELLULAR MATRIX PROTEIN PRODUCTION IN CHRONIC DIABETIC COMPLICATIONS: IMPLICATIONS OF NON-CODING RNAS. MANAGEMENT OF CHRONIC DIABETIC COMPLICATIONS REMAINS A MAJOR MEDICAL CHALLENGE WORLDWIDE. ONE OF THE CHARACTERISTIC FEATURES OF ALL CHRONIC DIABETIC COMPLICATIONS IS AUGMENTED PRODUCTION OF EXTRACELLULAR MATRIX (ECM) PROTEINS. SUCH ECM PROTEINS ARE DEPOSITED IN ALL TISSUES AFFECTED BY CHRONIC COMPLICATIONS, ULTIMATELY CAUSING ORGAN DAMAGE AND DYSFUNCTION. A CONTRIBUTING FACTOR TO THIS PATHOGENETIC PROCESS IS GLUCOSE-INDUCED ENDOTHELIAL DAMAGE, WHICH INVOLVES PHENOTYPIC TRANSFORMATION OF ENDOTHELIAL CELLS (ECS). THIS PHENOTYPIC TRANSITION OF ECS, FROM A QUIESCENT STATE TO AN ACTIVATED DYSFUNCTIONAL STATE, CAN BE MEDIATED THROUGH ALTERATIONS IN THE SYNTHESIS OF CELLULAR PROTEINS. IN THIS REVIEW, WE DISCUSSED THE ROLES OF NON-CODING RNAS, SPECIFICALLY MICRORNAS (MIRNAS) AND LONG NON-CODING RNAS (LNCRNAS), IN SUCH PROCESSES. WE FURTHER OUTLINED OTHER EPIGENETIC MECHANISMS REGULATING THE BIOGENESIS AND/OR FUNCTION OF NON-CODING RNAS. OVERALL, WE BELIEVE THAT BETTER UNDERSTANDING OF SUCH MOLECULAR PROCESSES MAY LEAD TO THE DEVELOPMENT OF NOVEL BIOMARKERS AND THERAPEUTIC STRATEGIES IN THE FUTURE. 2019 18 2352 25 EPIGENETIC REGULATION OF NRF2/KEAP1 BY PHYTOCHEMICALS. EPIGENETICS HAS PROVIDED A NEW DIMENSION TO OUR UNDERSTANDING OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2/KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (HUMAN NRF2/KEAP1 AND MURINE NRF2/KEAP1) SIGNALING. UNLIKE THE GENETIC CHANGES AFFECTING DNA SEQUENCE, THE REVERSIBLE NATURE OF EPIGENETIC ALTERATIONS PROVIDES AN ATTRACTIVE AVENUE FOR CANCER INTERCEPTION. THUS, TARGETING EPIGENETIC MECHANISMS IN THE CORRESPONDING SIGNALING NETWORKS REPRESENTS AN ENTICING STRATEGY FOR THERAPEUTIC INTERVENTION WITH DIETARY PHYTOCHEMICALS ACTING AT TRANSCRIPTIONAL, POST-TRANSCRIPTIONAL, AND POST-TRANSLATIONAL LEVELS. THIS REGULATION INVOLVES THE INTERPLAY OF HISTONE MODIFICATIONS AND DNA METHYLATION STATES IN THE HUMAN NFE2L2/KEAP1 AND MURINE NFE2L2/KEAP1 GENES, ACETYLATION OF LYSINE RESIDUES IN NRF2 AND NRF2, INTERACTION WITH BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) ACETYL "READER" PROTEINS, AND NON-CODING RNAS SUCH AS MICRORNA (MIRNA) AND LONG NON-CODING RNA (LNCRNA). PHYTOCHEMICALS DOCUMENTED TO MODULATE NRF2 SIGNALING ACT BY REVERSING HYPERMETHYLATED STATES IN THE CPG ISLANDS OF NFE2L2 OR NFE2L2, VIA THE INHIBITION OF DNA METHYLTRANSFERASES (DNMTS) AND HISTONE DEACETYLASES (HDACS), THROUGH THE INDUCTION OF TEN-ELEVEN TRANSLOCATION (TET) ENZYMES, OR BY INDUCING MIRNA TO TARGET THE 3'-UTR OF THE CORRESPONDING MRNA TRANSCRIPTS. TO DATE, FEWER THAN TWENTY PHYTOCHEMICALS HAVE BEEN REPORTED AS NRF2 EPIGENETIC MODIFIERS, INCLUDING CURCUMIN, SULFORAPHANE, RESVERATROL, RESERPINE, AND URSOLIC ACID. THIS OPENS AVENUES FOR EXPLORING ADDITIONAL DIETARY PHYTOCHEMICALS THAT REGULATE THE HUMAN EPIGENOME, AND THE POTENTIAL FOR NOVEL STRATEGIES TO TARGET NRF2 SIGNALING WITH A VIEW TO BENEFICIAL INTERCEPTION OF CANCER AND OTHER CHRONIC DISEASES. 2020 19 6152 26 THE FUNCTION OF NCRNAS IN RHEUMATIC DISEASES. RHEUMATIC DISEASES ARE A GROUP OF CHRONIC HETEROGENEOUS AUTOIMMUNE DISORDERS CHARACTERIZED BY ABNORMAL REGULATION OF THE INNATE AND ADAPTIVE IMMUNE SYSTEMS. DESPITE EXTENSIVE EFFORTS, THE FULL SPECTRUM OF MOLECULAR FACTORS THAT CONTRIBUTE TO THE PATHOGENESIS OF RHEUMATIC DISEASES REMAINS UNCLEAR. NCRNAS CAN GOVERN GENE EXPRESSION AT THE TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL LEVELS IN MULTIPLE DISEASES. RECENT STUDIES HAVE DEMONSTRATED AN IMPORTANT ROLE FOR NCRNAS, SUCH AS MIRNAS AND LNCRNAS, IN THE DEVELOPMENT OF IMMUNE CELLS AND RHEUMATIC DISEASES. HERE, WE FOCUS ON THE EPIGENETIC REGULATORY ROLES OF NCRNAS IN THE PATHOGENESIS OF RHEUMATIC DISEASES AND AS BIOMARKERS OF DISEASE STATE. 2019 20 1873 30 EMERGING ROLE OF MICRORNAS AND LONG NON-CODING RNAS IN SJOGREN'S SYNDROME. SJOGREN'S SYNDROME (SS) IS A CHRONIC AUTOIMMUNE INFLAMMATORY DISEASE. IT IS CONSIDERED A MULTIFACTORIAL PATHOLOGY, IN WHICH UNDERLYING GENETIC PREDISPOSITION, EPIGENETIC MECHANISMS AND ENVIRONMENTAL FACTORS CONTRIBUTE TO DEVELOPMENT. THE EPIGENETIC REGULATIONS REPRESENT A LINK BETWEEN GENETIC PREDISPOSITION AND ENVIRONMENTAL FACTORS. RECENT STUDIES SUGGESTED A REGULATORY ROLE FOR NON-CODING RNAS IN CRITICAL BIOLOGICAL AND DISEASE PROCESSES. AMONG NON-CODING RNAS, MICRORNAS (MIRNAS) AND LONG NON-CODING RNAS (LNCRNAS) PLAY A CRITICAL ROLE IN THE POST-TRANSCRIPTIONAL MRNA EXPRESSION, FORMING A COMPLEX NETWORK OF GENE EXPRESSION REGULATION. THIS REVIEW AIMS TO GIVE AN OVERVIEW OF THE LATEST STUDIES THAT HAVE INVESTIGATED THE ROLE OF MIRNAS AND LNCRNAS IN THE SS. WE INCLUDED PAPERS THAT INVESTIGATED THE EXPRESSION OF NON-CODING RNAS ON DIFFERENT TISSUES, IN PARTICULAR ON PERIPHERAL BLOOD MONONUCLEAR CELLS AND SALIVARY GLANDS. HOWEVER, REGARDING THE INVOLVEMENT OF NON-CODING RNAS GENETIC VARIABILITY IN SS SUSCEPTIBILITY VERY FEW DATA ARE AVAILABLE. FURTHER RESEARCH COULD HELP TO ELUCIDATE UNDERLYING PATHOGENIC PROCESSES OF SS AND PROVIDE NEW OPPORTUNITIES FOR THE DEVELOPMENT OF TARGETED THERAPIES. 2021